Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445088 in adults with chronic inflammatory demyelinating polyneuropathy
NL-OMON54382Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Sanofi. Primary endpoints: Relapse after SOC withdrawal during SAR445088 treatment, Response during SAR445088 treatment and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON54382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54382.